The short interest data are out for the February 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected stocks for this settlement date.
Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.97 million shares from the previous level of 10.63 million. Shares closed most recently at $140.90, in a 52-week trading range of $130.09 to $181.81.
Biogen Inc. (NASDAQ: BIIB) had its short interest decrease to 2.73 million from the previous level of 3.37 million. Shares closed Wednesday at $255.66, within a 52-week range of $242.07 to $480.18.
Celgene Corp. (NASDAQ: CELG) short interest for this settlement date increased to 13.34 million shares from the previous 11.74 million. Shares of Celgene closed most recently at $101.04, in a 52-week range of $92.98 to $140.72.
Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest fall to 36.31 million shares from 39.79 million in the previous period. Shares closed Wednesday at $87.83, in a 52-week trading range of $81.89 to $123.37.
MannKind Corp. (NASDAQ: MNKD) saw its short interest decrease to 117.26 million shares. The previous reading was 130.25 million. Shares closed most recently at $1.19, in a 52-week trading range of $0.64 to $7.32.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest increased to 5.84 million, compared to the previous level of 5.66 million. Shares closed most recently at $140.52, in a 52-week range of $130.51 to $208.88.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
